BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29987950)

  • 1. Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value.
    Liu J; Dong H; Yang Y; Qian Y; Liu J; Li Z; Guan H; Chen Z; Li C; Zhang K; Zhang Q; Cao W; Lv J
    Future Oncol; 2018 Dec; 14(29):3015-3022. PubMed ID: 29987950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
    Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
    Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
    Pang R; Yang S
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene.
    Li T; Yang XD; Ye CX; Shen ZL; Yang Y; Wang B; Guo P; Gao ZD; Ye YJ; Jiang KW; Wang S
    Cell Cycle; 2017 Jan; 16(2):224-231. PubMed ID: 27929737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
    Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
    J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations of ultrasound and pathological features of thyroid carcinoma with TC-1 mRNA and protein expression.
    Zhang CL; Geng CH; Jian JJ; He M; Zhao HW; Li HY
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3440-3446. PubMed ID: 31081098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
    Chen Y; Li Y; Gao H
    Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA H19 may be a marker for prediction of prognosis in the follow-up of patients with papillary thyroid cancer.
    Jiao X; Lu J; Huang Y; Zhang J; Zhang H; Zhang K
    Cancer Biomark; 2019; 26(2):203-207. PubMed ID: 31403942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
    Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis.
    Liu N; Zhou Q; Qi YH; Wang H; Yang L; Fan QY
    Exp Mol Pathol; 2017 Aug; 103(1):71-77. PubMed ID: 28655518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lncRNA GAS8-AS1 genetic alterations in papillary thyroid carcinoma and their clinical significance.
    Zhou DL; Liu Q; Xu BH; Li Y; Su X; Ye ZL; Zhang X; Peng JL; Deng L; Tang T; Shao Q; Ma JJ; Yang XH; He CY
    Cancer Biomark; 2020; 29(2):255-264. PubMed ID: 32675393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
    Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased expression of hsa_circ_0137287 predicts aggressive clinicopathologic characteristics in papillary thyroid carcinoma.
    Lan X; Cao J; Xu J; Chen C; Zheng C; Wang J; Zhu X; Zhu X; Ge M
    J Clin Lab Anal; 2018 Oct; 32(8):e22573. PubMed ID: 29790216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression and function of long noncoding RNA lncRNA-ATB in papillary thyroid cancer.
    Fu XM; Guo W; Li N; Liu HZ; Liu J; Qiu SQ; Zhang Q; Wang LC; Li F; Li CL
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3239-3246. PubMed ID: 28770959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
    Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
    BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
    Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
    OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma.
    Zhou GK; Zhang GY; Yuan ZN; Pei R; Liu DM
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8772-8780. PubMed ID: 30575918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
    Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
    Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LINC00311 promotes cancer stem-like properties by targeting miR-330-5p/TLR4 pathway in human papillary thyroid cancer.
    Gao Y; Wang F; Zhang L; Kang M; Zhu L; Xu L; Liang W; Zhang W
    Cancer Med; 2020 Feb; 9(4):1515-1528. PubMed ID: 31894666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
    Chen X; Jin J; Zheng L; Sheng Y; Sun J
    J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.